Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp., listed under the ticker EUCR, is a blank check company that completed its initial public offering in 2021 with an investment focus on the biomedical and life sciences sector. The company filed a Form 10-Q with the SEC on July 16, 2021, reflecting its status during the search phase following its IPO earlier that year. At the time of that quarterly filing, Eucrates remained a pre-combination SPAC evaluating potential acquisition targets within the biomedical industry. The filing provides a snapshot of the company's financial position and operational activity ahead of any announced transaction. Sign up at SpacDesk for full filing history, sponsor details, deal-stage tracking, and peer SPAC comparables.